Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables - Net: 2016-2024

Historic Receivables - Net for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $34.4 million.

  • Akebia Therapeutics' Receivables - Net rose 105.85% to $66.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.2 million, marking a year-over-year increase of 105.85%. This contributed to the annual value of $34.4 million for FY2024, which is 12.53% down from last year.
  • Akebia Therapeutics' Receivables - Net amounted to $34.4 million in FY2024, which was down 12.53% from $39.3 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Receivables - Net ranged from a high of $51.6 million in FY2021 and a low of $700,000 during FY2020.
  • In the last 3 years, Akebia Therapeutics' Receivables - Net had a median value of $39.3 million in 2023 and averaged $38.0 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first tumbled by 98.20% in 2020, then soared by 7,268.71% in 2021.
  • Yearly analysis of 5 years shows Akebia Therapeutics' Receivables - Net stood at $700,000 in 2020, then surged by 7,268.71% to $51.6 million in 2021, then declined by 21.90% to $40.3 million in 2022, then declined by 2.47% to $39.3 million in 2023, then decreased by 12.53% to $34.4 million in 2024.